Clinical Studies

2013 Zembrin fMRI studyHG&H have completed the following three rigorous randomised, double-blind placebo-controlled clinical trials, the first clinical trials ever to be done on a Sceletium product:

  1. A randomised double blind placebo controlled trial of extract Sceletium tortuosum (Zembrin®) in healthy adults. This study, by Nell et al. has been published in 2013 in the Journal of Alternative and Complementary Medicine. Click here for the abstract.
  2. Acute effects of extract Sceletium tortuosum (Zembrin®), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. This ground-breaking randomised, controlled crossover brain-imaging study found that a single dose of 25mg Zembrin® has significant effects on neural circuits involved in processing emotions. Research subjects were given Zembrin® or a placebo, and their brain’s responses to anxiety-provoking stimuli were monitored using computerised brain imaging (functional MRI). The full paper, published in the journal Neuropsychopharmacology, can be accessed here
  3. The effect of extract Sceletium tortuosum (Zembrin®), targeting Phosphodiesterase subtype-4 (PDE-4), on cognitive function: a proof-of-concept randomized double-blind, single site, placebo-controlled cross-over study in healthy adults. This study, by Chiu et al., will be submitted for peer-review for publication in 2013. The study was presented at the World Psychiatric Association Congress in Prague in October 2012, and at at the Natural Bioactives International Conference from July 9th-11th 2012, London Convention Centre, London, Ontario, Canada. Click here for the abstract.